Investigational drug · Phase 2
NKT2152
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Liver Cancers.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "NKT2152"
First trial start
2020
Nov 1, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NKT2152", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Liver Cancers
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "NKT2152" as an intervention, largest first.
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04524871 · 518 participants (planned) · Start Nov 1, 2020 · Primary completion Jul 30, 2027
Drug: Atezolizumab; Bevacizumab 15 mg/kg and 11 more · For: Advanced Liver Cancers
Sites: Costa Mesa, California; Duarte, California; Orange, California · 32 sites in all
- A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell CarcinomaPivotal-lookingTerminated
NiKang Therapeutics, Inc.Industry
NCT05119335 · 120 participants · Start Oct 26, 2021 · Primary completion Aug 22, 2025
Drug: Oral NKT2152 · For: ccRCC; Clear Cell Renal Cell Carcinoma; Kidney Cancer and 14 more
Sites: Scottsdale, Arizona; Los Angeles, California; Denver, Colorado · 13 sites in all
NiKang Therapeutics, Inc.Industry
NCT05935748 · 18 participants · Start Jul 28, 2023 · Primary completion Jun 30, 2025
Drug: NKT2152; palbociclib · For: ccRCC; Clear Cell Renal Cell Carcinoma; Kidney Cancer and 18 more
Sites: La Jolla, California; Chicago, Illinois; Boston, Massachusetts · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of NKT2152, a Potent and Selective HIF-2α Inhibitor with Favorable Pharmacokinetic Properties.
Fu J, He Y, Lu J, et al. · ACS Med Chem Lett 2026
- HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma.
Jiang M, Yamaguchi K, Hamada K, et al. · Int J Cancer 2026
- Targeting HIF-2α in renal cell carcinoma: Expanding upon belzutifan.
Rodriguez M, Qin Q, Tambar UK, et al. · Cancer 2026
- Targeting of HIF2-driven cachexia in kidney cancer.
Abu-Remaileh M, Stransky LA, Bhalerao N, et al. · Nat Med 2026
- HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors.
Abu-Remaileh M, Stransky LA, Bhalerao N, et al. · bioRxiv 2025
- Hypoxia Inducible Factor-2α (HIF-2α) Pathway Inhibitors.
Dogra R, Vaishampayan U · J Kidney Cancer VHL 2025
Also in development for Advanced Liver Cancers
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- TPST-1120Phase 32 trials
Roche (Genentech) · Advanced Liver Cancers, Hepatocellular Carcinoma (HCC)
- RO7247669Tobemstomig, RG6139Phase 26 trials
Roche (Genentech) · Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer
- ADG126Phase 23 trials
Adagene Inc · Advanced/Metastatic Solid Tumors, Solid Tumor, Advanced Liver Cancers
- IO-108Phase 21 trial
Roche (Genentech) · Advanced Liver Cancers
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.